GX BIO LABS · Product artwork
Tirzepatide (LY3298176) is a synthetic peptide studied for its activity at GIP and GLP-1 receptors and its role in incretin signalling.
Not currently available
Check COA availabilityCOA not yet available for this strength
Listed compound: tirzepatide (LY3298176), formerly displayed as TRIZ. Available catalogue strengths: 20 mg, 30 mg and 40 mg. Strength is the stated quantity per listed variant, not an administration dose. For laboratory research only; not for human or veterinary administration.
Not for human or veterinary administration. Listed strength is a supplied specification; see the matching batch report for measured results.
Tirzepatide, originally designated LY3298176, activates glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Published research examines receptor signalling, pancreatic islet responses and metabolic outcomes across laboratory models and controlled clinical studies.
The discovery programme characterised dual-receptor activity in experimental systems and early clinical research. Later mechanistic work examined receptor engagement and downstream signalling, while isolated human-islet experiments investigated the contribution of each receptor to hormone secretion. The SURPASS-2 and SURMOUNT-1 trials studied clinical formulations in defined patient populations.
This GX catalogue listing was previously named TRIZ. Its stated strengths are 20 mg, 30 mg and 40 mg. GX materials are listed for laboratory research only; the papers below did not test these GX vials or establish their batch identity, content or purity.
Listed compound: tirzepatide (LY3298176), formerly displayed as TRIZ. Available catalogue strengths: 20 mg, 30 mg and 40 mg. Strength is the stated quantity per listed variant, not an administration dose. For laboratory research only; not for human or veterinary administration.
Each source identifies what was studied and the limits of its findings. Published research is separate from this product’s batch COA.
Characterises LY3298176 in receptor assays and animal models alongside early clinical investigation. Provides foundational evidence for dual GIP and GLP-1 receptor activity.
Read studyExamines receptor engagement and downstream signalling, including cAMP responses, beta-arrestin recruitment and receptor internalisation.
Read studyInvestigates receptor contributions to hormone secretion in isolated islets and identifies species differences. Human donor tissue experiments are not clinical trials.
Read studyCompares clinical trial formulations in adults with type 2 diabetes, assessing glycaemic outcomes, body weight and adverse events. The trial did not evaluate GX research vials.
Read studyEvaluates a clinical trial formulation against placebo in adults with obesity or overweight without diabetes. Assesses body-weight outcomes and safety; the study did not test GX products.
Read studyTirzepatide is currently listed in 20 mg, 30 mg, 40 mg. Select a strength above to see its price, product image and current stock. Listed quantities are supplied specifications, not measured batch results.
No laboratory report is currently published for this compound. Request the available documentation before relying on any batch-specific measurement. A scientific paper is not a substitute for a COA.
A catalogue listing is not a laboratory measurement. Check original documentation for the selected strength and batch before relying on identity, purity or quantity information.
Retatrutide is a peptide that activates GIP, GLP-1 and glucagon receptors, studied in human trials of obesity and type 2 diabetes.